A virus-based vaccine may prevent cervical cancer

被引：14

作者：

Gravitt P.E. ^{[1
]}

Shah K.V. ^{[1
]}

机构：

[1] Dept. of Molec. Microbiol./Immunol., Johns Hopkins Bloomberg Sch. Public, Baltimore, MD 21205

来源：

Current Infectious Disease Reports | 2005年 / 7卷 / 2期

关键词：

Cervical Cancer; Cervical Intraepithelial Neoplasia; Natl Cancer Inst; Invasive Cervical Cancer;

D O I：

10.1007/s11908-005-0072-3

中图分类号：

学科分类号：

摘要：

High-risk human papillomaviruses (HPVs) are now recognized as the etiologic agents of invasive cervical cancer, a major cancer in women. A single HPV type (type 16) is responsible for about 50% of the cancers. The major capsid protein of papillomaviruses, LI, when expressed by recombinant DNA technology, has the intrisic ability to assemble into virus-like particles (VLPs). In a recent study, a vaccine based on HPV 16 VLPs was tested in a placebo-controlled proof-of-principle trial in young women in the United States. The vaccine was found to prevent 100% of incident persistent HPV 16 infections and HPV 16-associated cervical intraepithelial neoplasia. These results offer promise that cervical cancer will be preventable by an HPV-based vaccine. Studies planned or in progress are examining the efficacy of the vaccine in men, in HIV-infected individual, and in other parts of the world. Attempts are being made to prepare vaccines that can be administered more easily to large populations. Copyright © 2005 by Current Science Inc.

引用

页码：125 / 131

页数：6

共 40 条

[1]

Pisani P., Parkin D.M., Munoz N., Ferlay J., Cancer and infection: Estimates of the attributable fraction in 1990, Cancer Epidemiol. Biomarkers Prev., 6, pp. 387-400, (1997)

[2]

Huang K., Lin S., Nationwide vaccination: A sucess story in Taiwan, Vaccine, 18, SUPPL. 1, (2000)

[3]

Kao J.H., Chen D.S., Global control of hepatitis B virus infection, Lancet Infect. Dis., 2, pp. 395-403, (2002)

[4]

Walboomers J.M.M., Jacobs M.V., Manos M.M., Et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide, J. Pathol., 189, pp. 12-19, (1999)

[5]

Munoz N., Bosch F.X., Sanjose S., Et al., Epidemiologic classification of human papillomavirus types associated with cervical cancer, N. Engl. J. Med., 348, pp. 518-527, (2003)

[6]

Koutsky L.A., Ault K.A., Wheeler C.M., Et al., A controlled trial of a human papillomavirus type 16 vaccine, N. Engl. J. Med., 347, pp. 1645-1651, (2002)

[7]

Lowy D.R., Howley P.M., Papillomaviruses, Fields Virology, pp. 2231-2264, (2001)

[8]

Ho G.Y., Bierman R., Beardsley L., Et al., Natural history of cervicovaginal papillomavirus infection in young women, N. Engl. J. Med., 338, pp. 423-428, (1998)

[9]

Franco E.L., Villa L.L., Sobrinho J.P., Et al., Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer, J. Infect. Dis., 180, pp. 1415-1423, (1999)

[10]

Galloway D.A., Papillomavirus vaccines in clinical trials, Lancet Infect. Dis., 3, pp. 469-475, (2003)

← 1 2 3 4 →